Lannett Adds NovoLog Biosimilar As It Writes Off $198m Of Value
Portfolio Rationalization Leads To 23 Product Discontinuations
With ambitions of $1bn of sales by 2025, Lannett is looking to bolster its top-line further by expanding its co-development pact with China’s HEC Group for insulin biosimilar products. Management discussed the goal as Lannett presented financial results, which included a significant pre-tax loss.
